NCT07048886

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 68 (estimated)
• Sponsor: Center for Sight Las Vegas · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.

Detailed description

The study is a prospective single-practice with multiple locations, single-surgeon, parallel double arm study in subjects with open angle glaucoma (OAG), who were implanted with Hydrus microstent combined with cataract surgery to be randomized to receive Rocklatan vs. Comparator (artificial tears). Unmedicated MDIOP (mean diurnal intraocular pressure) measurements will be assessed at baseline (after Hydrus, prior to study medication) and at 1-month post-initiation of Study Drop.

Conditions

• Primary Open Angle Glaucoma

Interventions

Type	Name	Description
DRUG	Rocklatan (netarsudil 0.02% and latanoprost 0.005%)	Additional intraocular eye pressure lowering post-Hydrus
DRUG	Systane	Placebo Comparator (artificial tears)

Timeline

• Start date: 2025-07-15
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2025-07-03
• Last updated: 2025-07-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study